N/A N=47 Technology-Assisted Systems Change for Suicide Prevention
Suicide · Suicide, Attempted
Primary: Number of Participants With a Suicide Attempt in the Past Three Months — 0; 1; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,484 Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)
Pneumococcal Disease
Primary: Percentage of Participants With Solicited Injection-Site Adverse Events (AEs) — 4.7; 6.3; 39.0; 35.2 Percentage of Participants
N/A N=245 Effect of Compliance Counseling on Brace Success in Patients With Idiopathic Scoliosis
Adolescent Idiopathic Scoliosis
Primary: Brace Progress Report (i.e. Informing the Patient How Often They Were Wearing the Brace Versus Not Informing the Patient) — 93; 78; 26; 29 participants
Phase 1 N=10 Safety and Tolerability Study of MSC Exosome Ointment
Psoriasis
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 0 Participants
N/A N=110 Non-Pharmacological Treatments for Insomnia in Chronic Traumatic Brain Injury
Insomnia · Traumatic Brain Injury
Primary: Insomnia Severity Index (ISI) — -9.7; -4.72 Units on a scale
N/A N=154 Validation of Indiana's Early Evaluation Hub System
Autism
Primary: Agreement Between Composite Eye-tracking Biomarker and Expert Autism-specialist — 79; 10; 23; 34 Participants
N/A N=66 Angled-tip vs. Straight-tip Guidewire in Biliary Cannulation
Bile Duct Diseases
Primary: Cannulation — 30; 31 Participants
N/A N=113 Aerobic Plus Resistance Training and Insulin Sensitivity in African American Men
Insulin Resistance · Type 2 Diabetes
Primary: Insulin Response to an Oral Glucose Tolerance Test Over 20 Weeks. — 110.51; 106.64; 90.68; 80.23 uU/mL
N/A N=24 Smokers' Response to Nicotine Dependence Genotyping
Cigarette Smoking · Nicotine Dependence
Primary: Change in Baseline Smoking Abstinence at 6 and 10 Weeks After Genotyping Results — 1; 0; 7; 11 Participants
Phase 2 N=21 Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women
Vulvovaginal Atrophy · Vasomotor Symptoms
Primary: Number of Participants With Treatment Emergent Adverse Events — 11; 10 Participants
Phase 1 N=192 A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants
Hepatitis B, Chronic
Primary: Part 1: Percentage of Participants With Adverse Events — 27.3; 33.3; 50.0; 100 Percentage of participants
Phase 3 N=55 Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A
Congenital Bleeding Disorder · Haemophilia A
Primary: Number of Participants With Inhibitory Antibodies Against Coagulation Factor VIII (FVIII) — 11; 10 Participants
N/A N=733 Safer Use of Antipsychotics in Youth
Child Behavior Disorders
Primary: Percent of Youths With Antipsychotic Orders at 6 Months — 54.6; 47.6 percentage of youths
Phase 3 N=207 A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
Primary Immune Thrombocytopenia
Primary: Percentage of Participants With Chronic Immune Thrombocytopenia (ITP) With a Sustained Platelet Count Response Between Weeks 19 and 24 — 13.7; 16.2 percentage of…
N/A N=77 Exploring the Experience of Using a Prayer Mobile App
No Specific Condition. Feasibility of Mobile App
Primary: Acceptability of Mobile App — 4.5; 4.47; 4.14; 4.42 units on a scale